Replies to post #288422 on Kraig Biocraft Laboratories Inc (KBLB)

[igotthemojo]

"My problem is why didn't Dr. Kumar implement Diapause from the get go if it provides better silk and even bigger cocoons?"

perhaps this was the plan all along but it just wasnt told to shareholders...and maybe they were waiting for the 2 strain, double breasted, Bam 1, parental and orphaned worms....

the problem i see is that if these dont work, they will wait for the quad parental Pterodactyl strain to move forward...

but not to worry...it will probably only add another 6 months to the process...and if you complain, you know who, will ask what you dont understand about bitchin biotech and the genius moves being made...

[sickzone]

It was.
You need to check some facts before you start throwing failure around.

Kbl started the hybrid project in 2023.
They created 9 new strains, by the end of 2023 kbl narrowed it down to 6.
At the same time only 1 strain was homozygous for the spider silk transgene.

On February 6th 2024 kbl announced the creation of bam 1.
Homozygosity with the second parental strain of bam1 had still not been achieved.
February 27 they announced
Establishes Homozygosity and Confirms BAM 1 Hybrid Ready for Spring Production Trial.

You can't start with something that isn't ready.
It takes longer to develop a diapause transgenic than a non-diapause.

Kbl did what people wanted.
They used the quickest strains to develop bam 1 so they could produce spidersilk now instead of waiting for the perfect hybrid.

Kbl has finally reached the point where Dr Speers said in December
I’m even more excited for the many new hybrids we expect
to introduce over the next 12 months


From june 3 2025

The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world’s first development on schedule. This and many of our other laboratory announcements are not only significant; they’re foundational technology building blocks to our success.

Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders.